Evidence map›Paper›PMID 33667140›Full record

ReviewHuman vaccines & immunotherapeutics2021

Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma.

Yuexin Xu, Chris P Miller, Edus H Warren, Scott S Tykodi

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC).International journal of molecular sciences · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Yuexin XuClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-7140-6505
Chris P MillerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Edus H WarrenClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-9570-2755
Scott S TykodiClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-0399-0965
Fred Hutch Cancer Center · USUniversity of Washington · USUniversity of Washington Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In renal-cell carcinoma (RCC), tumor-reactive T-cell responses can occur spontaneously or in response to systemic immunotherapy with cytokines and immune checkpoint inhibitors. Cancer vaccines and engineered T-cell therapies are designed to selectively augment tumor antigen-specific CD8

Indexed as

Cancer VaccinesCarcinoma, Renal CellKidney NeoplasmsHumansImmunotherapyT-LymphocytesCancer Vaccinescancer vaccineRenal cell carcinomat cell receptortumor antigentumor-infiltrating T cell

Identifiers

PMID33667140
PMCPMC8189101
OpenAlexW3133685051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.